Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
IO Biotech, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
IOBT
Nasdaq
2834
www.iobiotech.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for IO Biotech, Inc.
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
- Feb 4th, 2025 1:05 pm
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy
- Jan 10th, 2025 4:10 pm
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
- Jan 9th, 2025 1:05 pm
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank
- Dec 20th, 2024 1:05 pm
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
- Nov 12th, 2024 12:05 pm
IO Biotech Announces Participation in Upcoming Investor Conferences
- Nov 11th, 2024 9:05 pm
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
- Nov 7th, 2024 3:00 pm
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation
- Nov 3rd, 2024 1:52 pm
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
- Oct 4th, 2024 1:00 pm
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
- Sep 14th, 2024 6:30 am
IO Biotech’s melanoma treatment trial to continue after IDMC review
- Sep 2nd, 2024 10:53 am
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
- Aug 30th, 2024 8:05 pm
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
- Aug 13th, 2024 11:05 am
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
- Jul 25th, 2024 8:05 pm
IO Biotech, Inc.'s (NASDAQ:IOBT) market cap touched US$104m last week, benefiting both private equity firms who own 59% as well as institutions
- Jul 21st, 2024 1:05 pm
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
- Jul 4th, 2024 2:01 pm
Will IO Biotech (NASDAQ:IOBT) Spend Its Cash Wisely?
- May 27th, 2024 12:18 pm
IO Biotech to Present at Jefferies Global Healthcare Conference
- May 23rd, 2024 12:30 pm
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
- May 14th, 2024 11:55 am
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apr 24th, 2024 8:30 pm
Scroll